Coccidioidal meningitis: Update on epidemiology, clinical features, diagnosis, and management

Current Infectious Disease Reports

Volumn 11, Issue 4, 2009, Pages 289-295

  Blair, Janis E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN; CORTICOSTEROID; FISH OIL; FLUCONAZOLE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MISOPROSTOL; PENTOXIFYLLINE; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ABDOMINAL PAIN; ANTIFUNGAL ACTIVITY; ARACHNOIDITIS; BACKACHE; BLEEDING; BRAIN DECOMPRESSION; BRAIN INFARCTION; BRAIN VASCULITIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; CLINICAL TRIAL; COCCIDIOIDES IMMITIS; COCCIDIOIDOMYCOSIS; CONCENTRATION RESPONSE; CYTODIAGNOSIS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PENETRATION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDEMIC DISEASE; FOOD; FOOD DRUG INTERACTION; FUNGICIDAL ACTIVITY; FUNGUS CULTURE; FUNGUS IMMUNITY; HISTOPATHOLOGY; HUMAN; HYDROCEPHALUS; INCIDENCE; INFECTION RISK; INNATE IMMUNITY; INSTILLATION SITE IRRITATION; MYELITIS; NEPHROTOXICITY; NEUROIMAGING; NONHUMAN; PATHOGENESIS; RELAPSE; REVIEW; RISK FACTOR; SERODIAGNOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 67649111383     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-009-0043-1     Document Type: Review

References (51)

1. Laniado-Laborin R: Expanding understanding of epidemiology of coccidioidomycosis in the Western hemisphere. Ann N Y Acad Sci 2007, 1111:19-34.
2. Smith CE, Beard RR: Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health 1946, 36:1394-1402.
3. Crum NF, LederAan ER, Stafford CM, et al.: Coccidioidomycosis: a descriptive survey of a reemerging disease. Clinical characteristics and current controversies. Medicine 2004, 83:149-175.
4. Johnson R, Caldwell JW, Welch G: The great coccidioidomycosis epidemic: clinical features. In Proceedings of the Fifth International Conference on Coccidioidomycosis. Edited by Einstein HE, Catanzaro A. Bethesda, MD: National Foundation for Infectious Diseases; 1996:77-87.
5. Cox RA, Magee HM: Coccidioidomycosis: host response and vaccine development. Clin Microbial Rev 2004, 17:804-839.
6. Johnson RH, Einstein HE: Coccidioidal meningitis. Clin Infect Dis 2006, 42:103-107.
7. Kelly PC: Coccidioidal meningitis. In: Coccidioidomycosis: A Text. Edited by Stevens DA. New York: Plenum; 1980:163-193.
8. Mischel PS, Vinters HV: Coccidioidomycosis of the central nervous system: Neuropathological and vasculopathic manifestations and clinical correlates. Clin Infect Dis 1995, 20:400-405.
9. Sunenshine RH, Anderson S, Erhart L, et al.: Public health surveillance for coccidioidomycosis in Arizona. Ann N Y Acad Sci 2007, 1111:96-102.
10. Arizona Department of Health Services: Infectious disease epidemiology. Available at http://azdhs.gov/phs/oids/epi/disease/cocci/index.htm. Accessed October 2008.
11. Vugia DJ, Wheeler C, Cummings KC, Karon A: Increase in Coccidioidomycosis - California, 2000-2007. MMWR Morb Mortal Wkly Rep 2009, 58:105-109.
12. Santelli AC, Blair JE, Roust LR: Coccidioidomycosis in patients with diabetes mellitus. Am J Med 2006, 119:964-969.
13. Vincent T, Galgiani JN, Huppert M, Salkin D: The natural history of coccidioidal meningitis: VA-Armed Forces cooperative studies, 1955-1958. Clin Infect Dis 1993, 16:247-254.
14. Arsura EL, Kilgore WB, Caldwell JW, et al.: Association between facial cutaneous coccidioidomycosis and meningitis. West J Med 1998, 169:13-16.
15. Banuelos AF, Williams PL, Johnson RH, et al.: Central nervous system abscesses due to Coccidioides species. Clin Infect Dis 1996, 22:240-250.
16. Winn W: CoccidioidaA meningitis: a followup report. In: Coccidioidomycosis Symposium on Coccidioidomycosis. Edited by Ajello L. Phoenix: University of Arizona Press; 1967:55-61.
17. Arsura EL, Johnson R, Penrose J, et al.: Neuroimaging as a guide to predict outcomes for patients with coccidioidal meningitis. Clin Infect Dis 2005, 40:624-627.
18. Kelly PC, Sievers M, Thompson R, Echols C: Coccidioidal meningitis: results of treatment in 22 patients. In: Coccidioidomycosis, Current Clinical and Diagnostic Status. Edited by Ajello L. Miami: Symposia Specialists; 1977:239-251.
19. Hagman HM, Madnick EG, D'Agostino AN, et al.: Hyphal forms in the central nervous system of patients with coccidioidomycosis. Clin Infect Dis 2000, 30:349-353.
20. Kelly PC: Coccidioidal meningitis. In: Coccidioidomycosis: Proceedings of the Fifth International Conference on Coccidioidomycosis. Edited by Einstein HE, Catanzaro A. Bethesda, MD: National Foundation for Infectious Diseases; 1996:373-384.
21. Dewsnup DH, Galgiani JN, Graybill JR, et al.: Is it ever safe to stop azole therapy for Coccidioides immitis meningitis? Ann Intern Med 1996, 124:305-310.
22. Ragland AS, Arsura E, Ismail Y, Johnson R: Eosinophilic pleocytosis in coccidioidal meningitis: Frequency and significance. Am J Med 1993, 95:254-257.
23. Meyer PR, Hui AN, Biddle M: Coccidioides immitis meningitis with arthroconidia in cerebrospinal fluid: Report of the first case and review of the literature. Hum Pathol 1982, 13:1136-1138.
24. Zepeda MR, Kobayashi GK, Appleman MD, Navarro A: Coccidioides immitis presenting as a hyphal form in cerebrospinal fluid. J Natl Med Assoc 1998, 90:435-436.
25. Erly WK, Bellon RJ, Seeger JF, Carmody RF: MR imaging of acute coccidioidal meningitis. AJNR Am J Neuroradiol 1999, 20:509-514.
26. Wrobel CJ, Meyer S, Johnson RH, Hesselink JR: MR findings in acute and chronic coccidioidomycosis meningitis. AJNR Am J Neuroradiol 1992, 13:1241-1245.
27. Wrobel CJ, Chappell ET, Taylor W: Clinical presentation, radiological findings, and treatment results of coccidioidomycosis involving the spine: Report on 23 cases. J Neurosurg 2001, 95:33-39.
28. Stevens DA, Shatsky SA: Intrathecal amphotericin in the management of coccidioidal meningitis. Semin Respir Infect 2001, 16:263-269.
29. Johnson RH, Einstein HE: Amphotericin B and coccidioidomycosis. Ann N Y Acad Sci 2007, 1111:434-441.
30. Capilla J, Clemons KV, Sobel RA, Stevens DA: Efficacy of amphotericin B lipid complex in a rabbit model of coccidioidal meningitis. J Antimicrob Chemother 2007, 60:673-676.
31. Clemons KV, Sobel RA, Williams PL, et al.: Efficacy of intravenous liposomal amphotericin B (AmBisome) against coccidioidal meningitis in rabbits. Antimicrob Agents Chemother 2002, 46:2420-2426.
32. Stevens DA, Clemons KV: Azole therapy of clinical and experimental coccidioidomycosis. Ann N Y Acad Sci 2007, 1111:442-454.
33. Graybill JR, Stevens DA, Galgiani JN, et al.: Ketoconazole treatment of coccidioidal meningitis. Ann N Y Acad Sci 1988, 544:488-496.
34. Classen DC, Burke JP, Smith CB: Treatment of coccidioidal meningitis with fluconazole. J Infect Dis 1988, 158:903-904.
35. Galgiani JN, Catanzaro A, Cloud GA, et al.: Fluconazole therapy for coccidioidal meningitis. The NIAID-Mycoses Study Group. Ann Intern Med 1993, 119:28-35.
36. Tucker RM, Galgiani JN, Denning DW, et al.: Treatment of coccidioidal meningitis with fluconazole. Rev Infect Dis 1990, 12(Suppl 3):S380-S389.
37. Perez JA Jr, Johnson RH, Caldwell JW, et al.: Fluconazole therapy in coccidioidal meningitis maintained with intrathecal amphotericin B. Arch Intern Med 1995, 155:1665-1668.
38. Duswald KH, Penk A, Pittrow L: High-dose therapy with fluconazole > or = 800 mg day-1. Mycoses 1997, 40:267-277.
39. Tucker RM, Denning DW, Dupont B, Stevens DA: Itraconazole therapy for chronic coccidioidal meningitis. Ann Intern Med 1990, 112:108-112.
40. Kamberi P, Sobel RA, Clemons KV, et al.: A murine model of coccidioidal meningitis. J Infect Dis 2003, 187:453-460.
41. Kamberi P, Sobel RA, Clemons KV, et al.: Comparison of itraconazole and fluconazole treatments in a murine model of coccidioidal meningitis. Antimicrob Agents Chemother 2007, 51:998-1003.
42. Antony SJ, Jurczyk P, Brumble L: Successful use of combination antifungal therapy in the treatment of coccidioides meningitis. J Natl Med Assoc 2006, 98:940-942.
43. Cortez KJ, Walsh TJ, Bennett JE: Successful treatment of coccidioidal meningitis with voriconazole. Clin Infect Dis 2003, 36:1619-1622.
44. Crum-Cianflone NF: Voriconazole in combination with amphotericin B for salvage therapy of coccidioidomycosis: Case report and review of the literature. Infect Dis Clin Pract 2007, 15:265-268.
45. Proia LA, Tenorio AR: Successful use of voriconazole for treatment of Coccidioides meningitis. Antimicrob Agents Chemother 2004, 48:2341.
46. Aperis G, Mylonakis E: NewerPtriazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Invest Drugs 2006, 15:579-602.
47. RachwalsAi EJ, Wieczorkiewicz JT, Scheetz MH: Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother 2008, 42:1429-1438.
48. Pitisuttithum P, Negroni R, Graybill JR, et al.: Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005, 56:745-755.
49. Williams PL: Vasculitic complications associated with coccidioidal meningitis. Semin Respir Infect 2001, 16:270-279.
50. Hsue G, Napier JT, Prince RA, et al.: Treatment of meningeal coccidioidomycosis with caspofungin. J Antimicrob Chemother 2004, 54:292-294.
51. Galgiani JN, Ampel NM, Blair JE, et al.: Coccidioidomycosis. Clin Infect Dis 2005, 41:1217-1223.